journal article·2023-06Open access

EGFR-antagonistic affibody-functionalized Pt-based nanozyme for enhanced tumor radiotherapy

Haijun Wang, Xichen Zhao, Heng Zhang, Xianwen Zou, Dianlong Jia, Wenjian Liu, Baoqing Tian, Dandan Yuan, Yihui Li, Yao Zhu, Fan Zhang, Yongsi Dai, Yu Fan, Yuchun Wei, Xiao Sun, Qing Fan, Jian Dong

Abstract

Clinical radiotherapy (RT) is severely limited by hypoxic tumor microenvironment and a lack of targeting precision. Therefore, it is crucial to develop highly efficient radiosensitizers to enhance RT efficacy. Herein, a novel kind of epidermal growth factor receptor (EGFR)-antagonistic affibody-functionalized Pt-based nanozyme for RT sensitization to EGFR-positive tumors was developed. In this study, porous platinum nanoparticles (pPt NPs) featuring catalase (CAT)-like activity and strong radiation energy absorption ability were first synthesized. Then, a thin biomimetic polydopamine (PDA) layer was coated on pPt NPs to optimize its biocompatibility as well as provide a reactive surface. Finally, a dimeric EGFR-antagonistic affibody called ZEGFR expressed by the Escherichia coli (E. coli), was conjugated to pPt@PDA NPs (termed pPt@PDA-ZEGFR NPs) to precisely recognize EGFR-positive A431 tumors. Under the navigation of ZEGFR, superior tumor homing was achieved with these Pt-based nanozymes, which was ascribed to EGFR receptor-mediated endocytosis. As high-Z metal NPs exhibit an inherently strong ability to absorb radiation energy and catalyze endogenous H2O2 in tumors, the pPt@PDA-ZEGFR NPs demonstrated superb therapeutic efficacy; specifically, the NPs significantly inhibited HIF-1α expression and increased RT-induced DNA damage. Furthermore, the biosafety of these Pt-based nanozymes was good during short-term treatment. In summary, EGFR-antagonistic affibody-functionalized Pt-based nanozymes are promising radiosensitizers for the precise therapy of EGFR-positive tumors.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (72)

Show source-provided references
1. Development of nanotechnology-mediated precision radiotherapy for anti-metastasis and radioprotection10.1039/D1CS01145F ↗
2. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy10.1073/pnas.030545097 ↗
3. FLASH radiotherapy: current knowledge and future insights using proton-beam therapy10.3390/ijms21186492 ↗
4. Induction of cell death by radiotherapy10.1677/erc.0.0060041 ↗
5. Scaling parameter of the lethal effect of mammalian cells based on radiation-induced OH radicals: effectiveness of direct action in radiation therapy10.1093/jrr/rraa111 ↗
6. Radiotherapy combination opportunities leveraging immunity for the next oncology practice
7. Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers10.1038/bjc.2011.240 ↗
8. Exploiting tumour hypoxia in cancer treatment
9. Microenvironment and radiation therapy10.1155/2013/685308 ↗
10. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence10.1038/nrc3958 ↗
11. Fluorinated hyaluronic acid encapsulated perfluorocarbon nanoparticles as tumor-targeted oxygen carriers to enhance radiotherapy10.1021/acs.molpharmaceut.2c00432 ↗
12. Coordination polymer-coated CaCO3 reinforces radiotherapy by reprogramming the immunosuppressive metabolic microenvironment10.1002/adma.202106520 ↗
13. Erythrocyte-Membrane-enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy10.1002/adma.201701429 ↗
14. An oxygen-enriched thermosensitive hydrogel for the relief of a hypoxic tumor microenvironment and enhancement of radiotherapy10.1039/D1BM01280K ↗
15. In vitro macrophage uptake and in vivo biodistribution of PLA–PEG nanoparticles loaded with hemoglobin as blood substitutes: effect of PEG content10.1007/s10856-009-3746-9 ↗
16. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance10.1016/j.biomaterials.2018.08.004 ↗
17. Au–Hemoglobin loaded platelet alleviating tumor hypoxia and enhancing the radiotherapy effect with low-dose X-ray10.1021/acsnano.0c06541 ↗
18. Nanozymes: classification, catalytic mechanisms, activity regulation, and applications10.1021/acs.chemrev.8b00672 ↗
19. Structure and activity of nanozymes: inspirations for de novo design of nanozymes10.1016/j.mattod.2020.08.020 ↗
20. Intrinsic peroxidase-like activity of ferromagnetic nanoparticles10.1038/nnano.2007.260 ↗
21. Biodegradable two-dimensional nanomaterials for cancer theranostics10.1016/j.ccr.2022.214415 ↗
22. Multifunctional MnO2 nanoparticles for tumor microenvironment modulation and cancer therapy10.1002/wnan.1720 ↗
23. Simultaneous Fenton-like ion delivery and glutathione depletion by MnO2-based nanoagent to enhance chemodynamic therapy10.1002/ange.201712027 ↗
24. Manganese-based hollow nanoplatforms for MR imaging-guided cancer therapies10.1186/s40824-022-00275-5 ↗
25. Biomimetic hybrid nanozymes with self-supplied H+ and accelerated O2 generation for enhanced starvation and photodynamic therapy against hypoxic tumors10.1021/acs.nanolett.9b00934 ↗
26. A mesoporous nanoenzyme derived from metal–organic frameworks with endogenous oxygen generation to alleviate tumor hypoxia for significantly enhanced photodynamic therapy10.1002/adma.201901893 ↗
27. Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy10.1186/s12951-021-00885-6 ↗
28. Radiotherapy enhancement with gold nanoparticles10.1211/jpp.60.8.0005 ↗
29. Emerging nanotechnology and advanced materials for cancer radiation therapy10.1002/adma.201700996 ↗
30. Engineering gold-based radiosensitizers for cancer radiotherapy10.1039/C7MH00451F ↗
31. A pH-responsive Pt-based nanoradiosensitizer for enhanced radiotherapy via oxidative stress amplification10.1039/D1NR02043A ↗
32. Porous platinum nanoparticles as a high-Z and oxygen generating nanozyme for enhanced radiotherapy in vivo10.1016/j.biomaterials.2019.01.004 ↗
33. Principles of cancer treatment by radiotherapy
34. Multidisciplinary strategies to enhance therapeutic effects of flavonoids from Epimedii Folium: integration of herbal medicine, enzyme engineering, and nanotechnology10.1016/j.jpha.2022.12.001 ↗
35. Ligand-targeted theranostic nanomedicines against cancer10.1016/j.jconrel.2016.01.002 ↗
36. Engineering folate–drug conjugates to target cancer: from chemistry to clinic10.1021/bc2005522 ↗
37. Radiolabelled RGD peptides for imaging and therapy10.1007/s00259-011-2028-1 ↗
38. Immunoconjugates for cancer targeting: a review of antibody-drug conjugates and antibody-functionalized nanoparticles10.2174/0929867327666200525161359 ↗
39. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB/c mice bearing TUBO tumors10.1016/j.ijpharm.2016.03.060 ↗
40. Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors10.1016/j.ijpharm.2022.121609 ↗
41. In vitro-engineered non-antibody protein therapeutics10.1007/s13238-017-0386-6 ↗
42. Preclinical and clinical safety of monoclonal antibodies, Drug Discov
43. Update: affibody molecules for molecular imaging and therapy for cancer
44. Development of HER2-targeting-ligand-modified albumin nanoparticles based on the SpyTag/SpyCatcher system for photothermal therapy10.1021/acs.biomac.1c00336 ↗
45. Affibody-attached hyperbranched conjugated polyelectrolyte for targeted fluorescence imaging of HER2-positive cancer cell10.1021/bm200563a ↗
46. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer10.1093/annonc/mdh011 ↗
47. TRAIL & EGFR affibody dual-display on a protein nanoparticle synergistically suppresses tumor growth10.1016/j.jconrel.2022.07.004 ↗
48. Antitumour immunity regulated by aberrant ERBB family signalling10.1038/s41568-020-00322-0 ↗
49. Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors10.1016/j.ijpharm.2022.121746 ↗
50. Improved discrimination of tumors with low and heterogeneous EGFR expression in fluorescence-guided surgery through paired-agent protocols
51. Identification of a suitable untargeted agent for the clinical translation of ABY-029 paired-agent imaging in fluorescence-guided surgery
52. Intraoperative detection of micrometastases in whole excised lymph nodes using fluorescent paired-agent imaging principles: identification of a suitable staining and rinsing protocol10.1007/s11307-021-01587-z ↗
53. Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models10.1016/j.ijpharm.2020.119541 ↗
54. Polydopamine-based simple and versatile surface modification of polymeric nano drug carriers10.1021/nn405809c ↗
55. Porous Pt nanoparticles loaded with doxorubicin to enable synergistic Chemo-/Electrodynamic Therapy10.1016/j.biomaterials.2020.120202 ↗
56. Combining photothermal therapy and immunotherapy against melanoma by polydopamine-coated Al2O3 nanoparticles10.7150/thno.24073 ↗
57. Epidermal growth factor receptor in glioma: signal transduction, neuropathology, imaging, and radioresistance10.1593/neo.10688 ↗
58. Phagocyte-membrane-coated and laser-responsive nanoparticles control primary and metastatic cancer by inducing anti-tumor immunity10.1016/j.biomaterials.2020.120159 ↗
59. Radiotherapy combined with immunotherapy: the dawn of cancer treatment10.1038/s41392-022-01102-y ↗
60. γH2AX foci analysis for monitoring DNA double-strand break repair: strengths, limitations and optimization10.4161/cc.9.4.10764 ↗
61. A polydopamine-coated platinum nanoplatform for tumor-targeted photothermal ablation and migration inhibition10.3389/fonc.2022.860718 ↗
62. Expanding global access to radiotherapy10.1016/S1470-2045(15)00222-3 ↗
63. Recent developments in radiotherapy10.1056/NEJMra1608986 ↗
64. Hypoxia as a biomarker for radioresistant cancer stem cells10.3109/09553002.2014.916841 ↗
65. Ligand-targeted therapeutics in anticancer therapy10.1038/nrc903 ↗
66. Ligand-targeted drug delivery10.1021/acs.chemrev.7b00013 ↗
67. Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy10.1002/elsc.202000027 ↗
68. Anti-EGFR therapies in nasopharyngeal carcinoma10.1016/j.biopha.2020.110649 ↗
69. Anti-EGFR antibody conjugated thiol chitosan-layered gold nanoshells for dual-modal imaging-guided cancer combination therapy10.1016/j.jconrel.2019.08.007 ↗
70. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors10.1002/cncr.22402 ↗
71. A versatile Pt-Ce6 nanoplatform as catalase nanozyme and NIR-II photothermal agent for enhanced PDT/PTT tumor therapy10.1007/s40843-020-1431-5 ↗
72. Porous Au@Pt nanoparticles: therapeutic platform for tumor chemo-photothermal Co-therapy and alleviating doxorubicin-induced oxidative damage10.1021/acsami.7b14705 ↗